159 related articles for article (PubMed ID: 29617059)
1. Aldo-keto reductases-mediated cytotoxicity of 2-deoxyglucose: A novel anticancer mechanism.
Zhang SQ; Yung KK; Chung SK; Chung SS
Cancer Sci; 2018 Jun; 109(6):1970-1980. PubMed ID: 29617059
[TBL] [Abstract][Full Text] [Related]
2. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of thioredoxin-1 enhances the toxicity of glycolysis inhibitor 2-deoxyglucose by downregulating SLC1A5 expression in colorectal cancer cells.
Tang T; Fang D; Ji Z; Zhong Z; Zhou B; Ye L; Jiang L; Sun X
Cell Oncol (Dordr); 2024 Apr; 47(2):607-621. PubMed ID: 37867183
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial electron transport chain blockers enhance 2-deoxy-D-glucose induced oxidative stress and cell killing in human colon carcinoma cells.
Fath MA; Diers AR; Aykin-Burns N; Simons AL; Hua L; Spitz DR
Cancer Biol Ther; 2009 Jul; 8(13):1228-36. PubMed ID: 19411865
[TBL] [Abstract][Full Text] [Related]
5. 2-Deoxyglucose induces the expression of thioredoxin interacting protein (TXNIP) by increasing O-GlcNAcylation - Implications for targeting the Warburg effect in cancer cells.
Hong SY; Hagen T
Biochem Biophys Res Commun; 2015 Oct; 465(4):838-44. PubMed ID: 26315267
[TBL] [Abstract][Full Text] [Related]
6. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives.
Liu J; Wen G; Cao D
Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):246-53. PubMed ID: 19522700
[TBL] [Abstract][Full Text] [Related]
7. Identification of the determinants of 2-deoxyglucose sensitivity in cancer cells by shRNA library screening.
Kobayashi H; Nishimura H; Matsumoto K; Yoshida M
Biochem Biophys Res Commun; 2015 Nov; 467(1):121-7. PubMed ID: 26403972
[TBL] [Abstract][Full Text] [Related]
8. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer.
Taskoparan B; Seza EG; Demirkol S; Tuncer S; Stefek M; Gure AO; Banerjee S
Cell Oncol (Dordr); 2017 Dec; 40(6):563-578. PubMed ID: 28929377
[TBL] [Abstract][Full Text] [Related]
9. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.
Ohashi T; Idogawa M; Sasaki Y; Suzuki H; Tokino T
Mol Cancer Res; 2013 Dec; 11(12):1554-63. PubMed ID: 24140838
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Anticancer Action of Lysosomal Membrane Permeabilization and Glycolysis Inhibition.
Kosic M; Arsikin-Csordas K; Paunovic V; Firestone RA; Ristic B; Mircic A; Petricevic S; Bosnjak M; Zogovic N; Mandic M; Bumbasirevic V; Trajkovic V; Harhaji-Trajkovic L
J Biol Chem; 2016 Oct; 291(44):22936-22948. PubMed ID: 27587392
[TBL] [Abstract][Full Text] [Related]
11. Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.
Huang L; He R; Luo W; Zhu YS; Li J; Tan T; Zhang X; Hu Z; Luo D
Recent Pat Anticancer Drug Discov; 2016; 11(2):184-96. PubMed ID: 26844556
[TBL] [Abstract][Full Text] [Related]
12. LINC00978 regulates metabolic rewiring to promote the malignancy of glioblastoma through AKR1B1.
Meng M; Yang L; Zhou H; Cheng Q; Peng R; Wang Z; Liang X; Wen J; Nie J; Hu Z; Zhang L; Liu Z
Cancer Lett; 2023 Jul; 567():216277. PubMed ID: 37336288
[TBL] [Abstract][Full Text] [Related]
13. 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
Sobhakumari A; Orcutt KP; Love-Homan L; Kowalski CE; Parsons AD; Knudson CM; Simons AL
Oncol Res; 2016; 24(1):55-64. PubMed ID: 27178822
[TBL] [Abstract][Full Text] [Related]
14. Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice.
Cheng Z; Levi J; Xiong Z; Gheysens O; Keren S; Chen X; Gambhir SS
Bioconjug Chem; 2006; 17(3):662-9. PubMed ID: 16704203
[TBL] [Abstract][Full Text] [Related]
15. Murine aldo-keto reductase family 1 subfamily B: identification of AKR1B8 as an ortholog of human AKR1B10.
Joshi A; Rajput S; Wang C; Ma J; Cao D
Biol Chem; 2010 Dec; 391(12):1371-8. PubMed ID: 21087085
[TBL] [Abstract][Full Text] [Related]
16. AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling.
Li J; Guo Y; Duan L; Hu X; Zhang X; Hu J; Huang L; He R; Hu Z; Luo W; Tan T; Huang R; Liao D; Zhu YS; Luo DX
Oncotarget; 2017 May; 8(20):33694-33703. PubMed ID: 28402270
[TBL] [Abstract][Full Text] [Related]
17. Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism.
Matsunaga T; Suzuki A; Kezuka C; Okumura N; Iguchi K; Inoue I; Soda M; Endo S; El-Kabbani O; Hara A; Ikari A
Chem Biol Interact; 2016 Aug; 256():142-53. PubMed ID: 27417252
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the efficacy of glycolytic blockade in cancer cells
Wilson JJ; Chow KH; Labrie NJ; Branca JA; Sproule TJ; Perkins BRA; Wolf EE; Costa M; Stafford G; Rosales C; Mills KD; Roopenian DC; Hasham MG
Cancer Biol Ther; 2019; 20(2):169-182. PubMed ID: 30183475
[TBL] [Abstract][Full Text] [Related]
19. p53 is an important factor for the radiosensitization effect of 2-deoxy-D-glucose.
Sinthupibulyakit C; Grimes KR; Domann FE; Xu Y; Fang F; Ittarat W; St Clair DK; St Clair W
Int J Oncol; 2009 Sep; 35(3):609-15. PubMed ID: 19639181
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Takemura M; Endo S; Matsunaga T; Soda M; Zhao HT; El-Kabbani O; Tajima K; Iinuma M; Hara A
J Nat Prod; 2011 May; 74(5):1201-6. PubMed ID: 21561086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
